VIRIDIAN THERAPEUTICS INC (VRDN)
US92790C1045 - Common Stock
Taking everything into account, VRDN scores 3 out of 10 in our fundamental rating. VRDN was compared to 565 industry peers in the Biotechnology industry. VRDN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, VRDN is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
VRDN had negative earnings in the past year.
VRDN had a negative operating cash flow in the past year.
VRDN had negative earnings in each of the past 5 years.
VRDN had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
VRDN's Return On Assets of -38.94% is in line compared to the rest of the industry. VRDN outperforms 58.47% of its industry peers.
VRDN's Return On Equity of -43.08% is fine compared to the rest of the industry. VRDN outperforms 71.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -38.94% | ||
| ROE | -43.08% | ||
| ROIC | N/A |
ROA(3y)-39.1%
ROA(5y)-67.96%
ROE(3y)-42.99%
ROE(5y)-97.25%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for VRDN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
VRDN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VRDN has more shares outstanding
VRDN has more shares outstanding than it did 5 years ago.
VRDN has a worse debt/assets ratio than last year.
2.2 Solvency
VRDN has an Altman-Z score of 15.30. This indicates that VRDN is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 15.30, VRDN belongs to the top of the industry, outperforming 90.37% of the companies in the same industry.
A Debt/Equity ratio of 0.03 indicates that VRDN is not too dependend on debt financing.
The Debt to Equity ratio of VRDN (0.03) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 15.3 |
ROIC/WACCN/A
WACC10.4%
2.3 Liquidity
A Current Ratio of 15.82 indicates that VRDN has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 15.82, VRDN belongs to the top of the industry, outperforming 89.66% of the companies in the same industry.
VRDN has a Quick Ratio of 15.82. This indicates that VRDN is financially healthy and has no problem in meeting its short term obligations.
VRDN has a Quick ratio of 15.82. This is amongst the best in the industry. VRDN outperforms 89.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 15.82 | ||
| Quick Ratio | 15.82 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 12.73% over the past year.
The Revenue for VRDN has decreased by -80.68% in the past year. This is quite bad
Measured over the past years, VRDN shows a very negative growth in Revenue. The Revenue has been decreasing by -48.16% on average per year.
EPS 1Y (TTM)12.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.69%
Revenue 1Y (TTM)-80.68%
Revenue growth 3Y-33.13%
Revenue growth 5Y-48.16%
Sales Q2Q%0%
3.2 Future
Based on estimates for the next years, VRDN will show a very strong growth in Earnings Per Share. The EPS will grow by 20.42% on average per year.
VRDN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 362.87% yearly.
EPS Next Y25.76%
EPS Next 2Y9.46%
EPS Next 3Y7.44%
EPS Next 5Y20.42%
Revenue Next Year-24.94%
Revenue Next 2Y-18.21%
Revenue Next 3Y382.04%
Revenue Next 5Y362.87%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
VRDN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VRDN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.46%
EPS Next 3Y7.44%
5. Dividend
5.1 Amount
No dividends for VRDN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VIRIDIAN THERAPEUTICS INC
NASDAQ:VRDN (11/15/2024, 8:00:01 PM)
After market: 19 -1.14 (-5.66%)20.14
-1.5 (-6.93%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.54B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -38.94% | ||
| ROE | -43.08% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 15.82 | ||
| Quick Ratio | 15.82 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)12.73%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y25.76%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-80.68%
Revenue growth 3Y-33.13%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y